haloperidol has been researched along with 3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Costain, WJ; Johnson, RL; Mishra, RK; Ott, MC | 1 |
| Chang, M; Gabriele, J; Henry, P; Johnson, RL; Mishra, RK; Paladino, P; Saeedi, H; Sharma, S | 1 |
2 other study(ies) available for haloperidol and 3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide
| Article | Year |
|---|---|
L-prolyl-l-leucyl-glycinamide and its peptidomimetic analog 3(R)-[(2(S)-pyrrolidylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) attenuate haloperidol-induced c-fos expression in the striatum.
Topics: Animals; Corpus Striatum; Gene Expression Regulation; Haloperidol; Hormone Antagonists; Male; Molecular Structure; MSH Release-Inhibiting Hormone; Peptides; Proto-Oncogene Proteins c-fos; Pyrrolidinones; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2000 |
Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia.
Topics: Administration, Oral; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Humans; Injections; Male; Mastication; MSH Release-Inhibiting Hormone; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Time Factors | 2003 |